AnalystsMichael Schmidt
Michael Schmidt's Stock Forecasts

Analyst Ranking
Top 11%
#519 out of 4906 analysts
Average Return
+12.03%
Win Rate
57%47 out of 82
Risk vs Reward
Poor
Good

Michael Schmidt's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Immunomedics IncIMMU
+235.60%$26.18$87.86
2020-04-23 -
2020-10-22
Strong Buy
Urogen Pharma LtdURGN
+187.11%$4.19$12.03
2025-05-23 -
2025-06-13
Strong Buy
Mirati Therapeutics IncMRTX
+182.05%$13.20$37.23
2017-11-14 -
2018-11-14
Buy
Forty Seven IncFTSV
+165.60%$35.96$95.51
2019-12-11 -
2020-04-06
Strong Buy
Adc Therapeutics SaADCT
+153.90%$1.41$3.58
2025-03-31 -
2025-06-13
Strong Buy

Michael Schmidt's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Adc Therapeutics SaADCT
4Strong Buy$10.00+179.33%Maintains
3 days ago
Urogen Pharma LtdURGN
1Strong Buy$15.00+24.69%Maintains
24 days ago
Mersana Therapeutics IncMRSN
3Strong Buy$5.00+1,262.40%Reiterates
a month ago
Kymera Therapeutics IncKYMR
1Strong Buy$52.00+10.73%Reiterates
a month ago
Springworks Therapeutics IncSWTX
3Hold$47.00+0.47%Reiterates
a month ago
Compass Therapeutics IncCMPX
3Strong Buy$10.00+314.94%Maintains
a month ago
Beone Medicines LtdONC
6Strong Buy$350.00+29.81%Maintains
a month ago
Revolution Medicines IncRVMD
3Strong Buy$80.00+97.09%Maintains
a month ago
Relay Therapeutics IncRLAY
1Strong Buy$10.00+210.56%Maintains
a month ago
Syndax Pharmaceuticals IncSNDX
3Strong Buy$32.00+212.20%Reiterates
a month ago
Arvinas IncARVN
3Strong Buy$16.00+116.51%Maintains
a month ago
Nanobiotix SaNBTX
2Strong Buy$8.00+49.67%Maintains
2 months ago
Merus NvMRUS
4Strong Buy$109.00+99.60%Reiterates
3 months ago
Adaptimmune Therapeutics PLCADAP
3Strong Buy$1.75+623.14%Maintains
3 months ago
Verastem IncVSTM
2Strong Buy$14.00+150.00%Maintains
3 months ago
Immunome IncIMNM
2Strong Buy$25.00+171.74%Maintains
3 months ago
Incyte CorpINCY
4Hold$92.00+35.79%Downgrades
3 months ago
Arrivent Biopharma IncAVBP
1Strong Buy$45.00+93.38%Initiates Coverage On
3 months ago
Exelixis IncEXEL
6Strong Buy$42.00+0.99%Reiterates
4 months ago
Protara Therapeutics IncTARA
1Strong Buy$20.00+536.94%Reiterates
6 months ago
Zentalis Pharmaceuticals IncZNTL
3Strong Buy$8.00+497.01%Maintains
7 months ago
Immunocore Holdings PLCIMCR
2Strong Buy$92.00N/AReiterates
a year ago
Immunogen IncIMGN
1Hold$31.00N/ADowngrades
2 years ago
Xencor IncXNCR
2Strong Buy$34.00N/AMaintains
2 years ago
Mirati Therapeutics IncMRTX
4Strong Buy$60.00N/AMaintains
2 years ago
Adicet Bio IncACET
3Hold$20.00N/ADowngrades
2 years ago
Blueprint Medicines CorpBPMC
1Strong Buy$82.00N/AMaintains
2 years ago
Oric Pharmaceuticals IncORIC
2Hold$15.00N/ADowngrades
2 years ago
Seagen IncSGEN
3Strong Buy$170.00N/AReiterates
2 years ago
Deciphera Pharmaceuticals IncDCPH
1Strong Buy$22.00N/AUpgrades
2 years ago
Neurogene IncNGNE
2HoldN/AN/ADowngrades
3 years ago
Rubius Therapeutics IncRUBY
2HoldN/AN/ADowngrades
3 years ago
Immuneering CorpIMRX
1Strong Buy$42.00N/AInitiates Coverage On
4 years ago
Erasca IncERAS
1Strong Buy$25.00N/AInitiates Coverage On
4 years ago
Monte Rosa Therapeutics IncGLUE
1Strong Buy$30.00N/AInitiates Coverage On
4 years ago
Rain Oncology IncRAIN2
1Strong Buy$26.00N/AInitiates Coverage On
4 years ago
Cellectis SaCLLS
1HoldN/AN/ADowngrades
4 years ago
Bolt Biotherapeutics IncBOLT
1Strong Buy$840.00N/AInitiates Coverage On
4 years ago
Immunomedics IncIMMU
1Strong Buy$39.00N/AMaintains
5 years ago
Spectrum Pharmaceuticals IncSPPI
1HoldN/AN/ADowngrades
5 years ago
Forty Seven IncFTSV
1Strong Buy$48.00N/AMaintains
6 years ago
Bluebird Bio IncBLUE
4HoldN/AN/ADowngrades
6 years ago
Agios Pharmaceuticals IncAGIO
3Buy$80.00N/AUpgrades
6 years ago
Clovis Oncology IncCLVSQ
2Hold$30.00N/AInitiates Coverage On
7 years ago
Five Prime Therapeutics IncFPRX
1Buy$24.00N/AReinstates
7 years ago
Array Technologies IncARRY
1Buy$20.00N/AMaintains
7 years ago
Juno Therapeutics IncJUNO
2Hold$87.00N/ADowngrades
7 years ago
Arbutus Biopharma CorpABUS
1Hold$5.50N/AMaintains
8 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.